We are global leaders in the design, manufacture, and application of gene editing and gene modulation, building cell models that harbour the genetics of human disease. These cells are the basis of our broad range of products and services, providing researchers and drug developers alike with the critical insights they need to drive the development and effective application of personalised medicines and cell and gene therapies.
Transformational acquisition of Dharmacon adding gene modulation capabilities.
Deepening of gene editing capabilities through novel Transposon technology and expansion of CRISPR licences.
Significant strengthening of commercial team who are unlocking value for customers.
In compliance with AIM rule 26, this section of Horizon’s website contains important information for investors including business description, details of Directors and advisors, news for investors, and share information. Horizon Discovery Group plc is incorporated in England with its main country of operation being the United Kingdom and additional headquarters in the United States of America and is listed on the London Stock Exchange’s AIM market under the ticker HZD. Horizon Discovery Group plc is subject to the UK City Code on Takeovers and Mergers. Horizon Discovery Group plc’s shares are currently only traded on AIM. There are currently no restrictions on the transfer of securities.